sCR1sLe(X) reduces lung allograft ischemia-reperfusion injury but does not ameliorate acute rejection.
BACKGROUND
Combined inhibition of complement and leukocyte adhesion by sCR1sLe(X) reduces lung allograft dysfunction up to 24 h. In the present study its effect on graft function and acute rejection was evaluated up to 5 days after experimental transplantation.


METHODS
Orthotopic single left lung transplantation was performed in 35 male rats (Brown Norway to Fischer 344) after a total ischemic time of 20 h. Two groups were assessed after 1, 3, and 5 days post-transplant, respectively (n=5 per group and time point): controls vs. recipients which received 10 mg/kg sCR1sLe(X) 15 min prior to reperfusion. In addition, five animals received 10 mg/kg per day sCR1sLe(X) for 5 days. For blood gas analysis of the graft, the contralateral lung was occluded for 5 min to assess graft function. Lung grafts were flushed, and histological grading was performed in blinded fashion according to the International Society for Heart and Lung Transplantation criteria.


RESULTS
Graft PaO(2) in recipients treated with sCR1sLe(X) was superior on day 1 (383+/-118 vs. 56+/-15 mmHg; P<0.0001) and day 3 (446+/-48 vs. 231+/-108 mmHg; P<0.0001). Five days after transplantation, no difference in PaO(2) was found (61+/-28 vs. 83+/-31 mmHg; P=0.59). Repeated treatment with sCR1sLe(X) for 5 days did not improve PaO(2) (64+/-5 mmHg; P=0.65 vs. control; P=0.93 vs. sCR1sLe(X)). At any time point, there was no difference in the degree of rejection between groups.


CONCLUSIONS
In this model sCR1sLe(X) provided marked improvement of graft function up to 3 days, but inhibition of both complement system and selectin dependent leukocyte adhesion failed to protect against acute rejection.
Stammberger
Uz
U
Division of General Thoracic Surgery, University Hospital Berne, 3010 Berne, Switzerland.
Hamacher
Jürg
J
Pache
Jean-Claude
JC
Schmid
Ralph A
RA
D000818:Animals; D003169:Complement Inactivator Proteins / Q000627:therapeutic use*; D006084:Graft Rejection / Q000473:pathology*; D016040:Lung Transplantation; D008297:Male; D010100:Oxygen / Q000097:blood; D051381:Rats; D011914:Rats, Inbred BN; D011916:Rats, Inbred F344; D011951:Receptors, Complement / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000517:prevention & control*
D003169:Complement Inactivator Proteins; D011951:Receptors, Complement; D011994:Recombinant Proteins; C082885:soluble complement inhibitor 1; D010100:Oxygen